ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PARP-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PARP-inhibitor
30
trial(s) found.
NCT06909825
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (
FPI-2265-203
)
PARP inhibitor
radioligand,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06433219
Advanced
Phase 2
Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) (
MS201924-0002
)
ATM inhibitor
ATR inhibitor
PARP inhibitor
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06353386
Advanced
Phase 1 / Phase 2
Recruiting
MK-
5684-01A
Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
CYP11A1 inhibitor
+ PARP inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06253130
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors (
IMP1734-101
)
PARP1-selective inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast Private Hospital
NCT06220864
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors (
SNV1521-101
)
PARP1-selective inhibitor
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06120491
Advanced
Phase 3
Recruiting
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) (
EvoPAR-PR01
)
PARP1-selective inhibitor
placebo
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (TERMINATED)
2031 - Randwick - Prince of Wales Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Glandore - Ashford Cancer Centre
NCT06112379
Curative
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (
D926QC00001
; TROPION-Breast04)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ PARP inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
+ PARP1-selective inhibitor
Lung adenocarcinoma
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05417594
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
CERTIS1
)
PARP1-selective inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05367440
Advanced
Phase 1 / Phase 2
Recruiting
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (
PETRANHA
)
PARP1-selective inhibitor
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05269316
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors (
IMP9064-101
)
ATR inhibitor
PARP inhibitor
NOT Central nervous system cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research (COMPLETED)
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
+ PARP1-selective inhibitor
Biliary tract cancer
Breast cancer
Endometrial cancer
Ovarian cancer
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05053854
Advanced
Phase 1
Recruiting
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor (
PARLuNET
)
PARP inhibitor
Talazoparib
cancer therapy
cancer therapy,PARP-targeting
+ PARP inhibitor
Neuroendocrine tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04985721
Advanced
Phase 2
Recruiting
An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (
IMPARP-HRD
)
PARP inhibitor
anti-PD-1 monoclonal antibody
Cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03874884
Advanced
Phase 1
Recruiting
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (
LuPARP
)
PARP inhibitor
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
+ PARP inhibitor
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (SUSPENDED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ PARP inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ PARP inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12623000657628
Curative
Phase 2
Recruiting
BCT 2301 (
OLIO
): A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer
PARP inhibitor
anti-PD-L1 monoclonal antibody
Breast cancer
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
+ PARP inhibitor
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12616000689471
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid Tumors (
IMP4297-2016-AU01
)
PARP inhibitor
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06509906
Advanced
Phase 1
Suspended
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (
MS202650-0001
)
PARP1-selective inhibitor
Colorectal adenocarcinoma
NOT Colorectal adenocarcinoma
Solid tumour
NSW
2217 - Kogarah - St George Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05498155
Curative
Phase 2
Active not recruiting
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer (
OlympiaN
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05425862
Advanced
Phase 1
Suspended
Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (
REPAIR
)
PARP inhibitor
RNA polymerase I transcription inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
NCT05252390
Advanced
Phase 1 / Phase 2
Not recruiting
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (
NUV-868-01
)
BET inhibitor
PARP inhibitor
antiandrogen,nonsteroidal,second generation
Breast cancer
Cancer
Castrate-resistant prostate cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04822961
Advanced
Phase 2
Unknown
A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment (
IMP4297-202
)
PARP inhibitor
placebo
taxane
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Suspended (2)
Enrolling by invitation (1)
Active not recruiting (1)
Not recruiting (1)
Unknown (1)
Recruitment Country and State
VIC (25)
NSW (24)
QLD (12)
WA (8)
SA (7)
NZ (4)
TAS (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (10)
Phase 2 (8)
Phase 3 (5)
Trial Type
Advanced (27)
Curative (3)
Cancer Therapy Class
PARP
100%
PD-1/PD-L1
33%
PARP1-selective
33%
PD-1
23%
androgen axis
20%
VEGF
20%
AR
17%
PD-L1
13%
ERBB2
13%
CYP17A1
13%
oestrogen axis
10%
Trop2
10%
TIGIT
10%
ATR
7%
ER
7%
LAG3
7%
PSMA
3%
ATM
3%
CDK4
3%
CDK6
3%
CYP11A1
3%
FR-alpha
3%
B7H4
3%
HPK1
3%
KIT
3%
OX40
3%
PDGFR
3%
RET
3%
VEGFR
3%
VEGFR1
3%
VEGFR2
3%
VEGFR3
3%
HIF2a
3%
HMG-CoA reductase
3%
CTLA4
3%
PI3K-delta
3%
PI3K
3%
PI3Kalpha
3%
XPO1
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
RNA polymerase I
3%
BET
3%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (18)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
2109 - North Ryde - Macquarie University Hospital (7)
4102 - Woolloongabba - Princess Alexandra Hospital (7)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
3168 - Clayton - Monash Medical Centre (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
2170 - Liverpool - Liverpool Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
3004 - Melbourne, Southbank - Alfred Health (4)
2031 - Randwick - Prince of Wales Hospital (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
6009 - Nedlands - Linear Clinical Research (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
3002 - East Melbourne - Epworth Freemasons (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3066 - Epping - Northern Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2500 - Wollongong - Wollongong Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4215 - Southport - Gold Coast Private Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5037 - Glandore - Ashford Cancer Centre (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4215 - Southport - Tasman Oncology (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2217 - Kogarah - St George Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Male genital cancers
Prostate cancer
Urogenital cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Breast cancer
Gastrointestinal cancer
Gynaecological cancer
Ovarian cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Biliary tract cancer
Hepatobiliary cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Endometrial cancer
Colorectal cancer
Lower gastrointestinal cancer
Pancreatic cancer
Cholangiocarcinoma
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
Squamous non-small-cell lung cancer
Neuroendocrine tumour
Bladder cancer
Carcinoma
Cervical cancer
Gastric cancer
Gastroesophageal cancer
HPV-related cancer
HPV16-positive cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Viral-related cancer
Haematological malignancy
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
Colorectal adenocarcinoma
Breast adenocarcinoma
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy